Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Nanobiotix S.A. - ADSs (NBTX)
Company Research
Source: GlobeNewswire
Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of survival data showed 12-month LPFS of 64% (median 18.6 months) and 12-month OS of 83% (median 30.2 months)The dose escalation part is complete, and 5/12 patients have been injected to date in the ongoing expansion part PARIS and CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering disruptive, nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the first data from the completed dose escalation part of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center ("MD Anderson") evaluating radiotherapy-activated NBTXR3 (JNJ-1900)1 as a second or later line (2L+) therapy for patients with locally advanced
Show less
Read more
Impact Snapshot
Event Time:
NBTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBTX alerts
High impacting Nanobiotix S.A. - ADSs news events
Weekly update
A roundup of the hottest topics
NBTX
News
- Voting Rights and Shares Capital of the CompanyGlobeNewswire
- NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris [Yahoo! Finance]Yahoo! Finance
- NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext ParisGlobeNewswire
- Nanobiotix (NASDAQ:NBTX) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical OutlookGlobeNewswire
NBTX
Sec Filings
- 12/17/25 - Form 6-K
- 12/15/25 - Form 6-K
- 12/1/25 - Form 6-K
- NBTX's page on the SEC website